Big Pharma Engages Trump Administration in Active Drug Pricing Talks

President Donald Trump has been actively demanding lower drug prices in the U.S., threatening penalties and tariffs on pharmaceutical companies that do not comply, aiming to make medicines more affordable for Americans. Major pharmaceutical CEOs, including Pfizer's Albert Bourla, have acknowledged ongoing, serious discussions with the Trump administration and expressed willingness to cooperate constructively, despite concerns over trade policy volatility and the impact of tariffs. Bourla, who is also chair of the industry lobbying group PhRMA, emphasized collaborative efforts to expand direct-to-consumer drug options and reduce costs, as seen with Pfizer's initiative to lower prices on some medications like the blood thinner Eliquis. Meanwhile, criticisms have emerged about the relationship between Trump and pharma executives, highlighting Bourla's attendance at a Trump fundraiser despite public distrust among some MAGA supporters. Additionally, Health and Human Services Secretary Robert F. Kennedy has taken steps to improve public health by canceling costly mRNA vaccine contracts and working with states to remove unhealthy foods from federal assistance programs, though concerns remain about Big Pharma's influence on drug pricing programs like 340B that benefit rural hospitals. These developments reflect a complex interplay between political leadership, pharmaceutical industry actions, and public health policy amid ongoing debates over drug affordability and corporate accountability.